Phase 4
Completed N=182
Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Source: ClinicalTrials.gov NCT04702776 ↗Enrolled (actual)
182
Serious AEs
0.5%
Results posted
Jan 2026
Primary outcomePrimary: Change in Ocular Surface Disease Index (OSDI) — 26.4; 26.3; 26.6; 16.4 score on a scale
◆ Published Evidence
Emerging
8citations · ~4 / year
Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease.
Summary
Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in patients with mild to moderate dry eye disease.
Linked Publications
-
Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Ocular Surface Disease Index (OSDI) |
26.4; 26.3; 26.6; 16.4; 14.0; 15.2 | — |
| SECONDARY Noninvasive Keratograph Break-up Time (NIKBUT) |
6.8; 5.2; 7.1; 7.3; 6.9; 7.7 | — |
| SECONDARY Change of Conjunctival and Corneal Staining With Lissamine Green |
20; 23; 16; 21; 22; 24 | — |
| SECONDARY Change of Conjunctival and Corneal Staining With Fluorescein |
19; 20; 16; 19; 27; 20 | — |
| SECONDARY Change in Conjunctival Hyperemia |
21; 15; 14; 14; 17; 12 | — |
| SECONDARY Incidence of Related Non Expected Adverse Events |
5; 5; 10 | — |
| SECONDARY Change in Best Corrected Visual Acuity (BCVA) |
0.97; 0.95; 0.94; 0.99; 0.98; 0.96 | — |
| SECONDARY Change in Incidence of Chemosis |
0; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Being capable of voluntarily grant a signed informed consent.
- Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
- Age ≥ 18 years old
- Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study.
- Presenting a mild to moderate dry eye disease diagnosis, defined as:
- OSDI score ≥ 13, plus one of the following:
- More than 5 dots of corneal staining
- More than 9 dots of conjunctival staining
- Tear break-up time < 10 seconds
Exclusion Criteria
- - Pregnancy, breastfeeding or planning to become pregnant during the time of the study
- Having participated in clinical trials within 30 days prior to the eligibility visit.
- Having participated previously in this study.
- BCVA equal or worse than 20/200, in either eye.
- Diagnosis of any of the following:
- Allergic, viral or bacterial conjunctivitis
- Anterior blepharitis
- Parasite infestation of any ocular or annex structures (Demodex, for example)
- Unresolved history of ocular trauma
- Scarring diseases of the ocular surface
- Corneal or conjunctival ulcers
- Filamentary keratitis
- Neurotrophic keratitis
- Bullous keratopathy
- Neoplastic diseases of the ocular surface or ocular annexes
- Diseases presenting fibrovascular proliferations on the corneal or conjunctival surface.
- Any retinal or posterior segment diseases that require treatment or threat the visual outcome.
- Glaucoma
- Any palpebral alteration that causes eyelid malposition, limiting the adequate closure or aperture of this structures, or that cause tearing.
- Requiring management for dry eye that includes implementation of treatments described in the step 2 management recommendations of the Tear Film & Ocular Surface Society's Dry Eye Work Shop II (TFO DEWS II).
- Previous history of drug addiction within the last 2 years prior to signing this study's informed consent form.
- Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
- Being a contact lens user, rigid or soft. Inclusion is possible if the use of contact lenses is suspended both during the study period and at least 15 days prior inclusion takes place.
- Previous history of any medical affliction, acute or chronic, that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
- Known hypersensitivity to any of the components of the products used in this study.
Data sourced from ClinicalTrials.gov (NCT04702776) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.